A:Head Bio AG Incorporated To Use Cerebral Organoids For CNS Drug Discovery

Pixabay License | Source:  holdentrils , no changes made.
Advertisement

a:head bio AG, an Austrian biotech company focused on the development of next generation therapeutics for the treatment of brain disorders based on human cerebral organoids has recently been incorporated. The new venture is based on groundbreaking technology developed at the Institute of Molecular Biotechnology GmbH (IMBA) in Vienna, Austria and substantially funded by red-stars.com data AG, a Viennese high-tech holding company.

Founded in 2003, IMBA – Institute of Molecular Biotechnology – is one of the leading biomedical research institutes in Europe focusing on cutting-edge stem cell technologies, functional genomics, and RNA biology. IMBA is located at the Vienna BioCenter, the vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research. The stem cell and organoid research at IMBA is being funded by the Austrian Federal Ministry of Science and the City of Vienna.

Founded in 2000, red-stars.com data AG is an operative holding company based in Vienna, Austria, engaged in the global penetration of highly scalable innovative technologies, utilizing & commercializing scientific IP and software.

a:head has been co-founded by Jürgen Knoblich, IMBA´s scientific director and neuroscientist Madeline Lancaster from the MRC Laboratory of Molecular Biology (LMB), Cambridge, UK, who have been pioneering 3D in vitro modeling of the human brain to study psychiatric disorders.

“CNS drug discovery is amongst the most challenging endeavours in the pharmaceutical industry,” … “however, our disruptive technology using complex human brain tissue for drug design has the potential to herold a new era in the development of novel medicines for the treatment of brain diseases.” – Oliver Szolar, founding partner and CEO, a:head

“We are very excited to have the opportunity to accompany a:head right from the beginning. We were immediately infected by this game changing technology and the spirit of the founders, both of which are important ingredients of a future success story.” – Thomas Streimelweger, CEO of red-stars.com data AG and a:head’s chairman of the supervisory board

“Our cerebral organoids are a fascinating new tool that allows us to study neuro-psychiatric disorders in innovative ways we could not even imagine before.” … “Now a:head will use this technology for the development of novel CNS therapeutics in a variety of underserved indications.” Jürgen Knoblich, chairman of a:head’s scientific advisory board

Sources

  1. https://www.imba.oeaw.ac.at/about-imba/general-news-press/ahead-bio-launched-to-transform-cns-drug-discovery/
  2. https://www.viennabiocenter.org/about/vbc-at-a-glance/who-is-here-members/institute-of-molecular-biotechnology-imba/
  3. https://www.bloomberg.com/profile/company/RSTAR:AV
Advertisement

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.